Dartmouth Hitchcock Medical Center (DHMC)
Welcome,         Profile    Billing    Logout  
 3 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rigby, William FC
RAMBA, NCT03652961: Rheumatoid Arthritis Memory B Cells and Abatacept

Completed
4
25
US
Abatacept, DMARDs
NYU Langone Health, Dartmouth-Hitchcock Medical Center, Bristol-Myers Squibb
Rheumatoid Arthritis
09/21
09/21
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
R-2487-RA01, NCT05961592: R-2487 in Patients with Rheumatoid Arthritis

Recruiting
1
36
US
R-2487, Drug
Rise Therapeutics LLC
Arthritis, Rheumatoid
11/25
01/26
Brooker, Jill
R-2487-RA01, NCT05961592: R-2487 in Patients with Rheumatoid Arthritis

Recruiting
1
36
US
R-2487, Drug
Rise Therapeutics LLC
Arthritis, Rheumatoid
11/25
01/26
Torres, Gustavo
R-2487-RA01, NCT05961592: R-2487 in Patients with Rheumatoid Arthritis

Recruiting
1
36
US
R-2487, Drug
Rise Therapeutics LLC
Arthritis, Rheumatoid
11/25
01/26
NCT05845255: Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data

Recruiting
N/A
130
Europe
mjn-SERAS
MJN Neuroserveis, S.L, Clinica Universidad de Navarra, Universidad de Navarra, Oxford University Hospitals NHS Trust, Diakonie Kork, Clínica Corachan
Quality of Life, Epilepsy (treatment Refractory)
12/24
06/25
Gomez, Simon
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Recruiting
2
598
US
STRI Formula, Placebo
Eyecheck, Inc.
Covid19
12/22
08/23
NCT05666960: R-3750 in Patients With Mild to Moderate Ulcerative Colitis

Recruiting
1
36
US
R-3750
Rise Therapeutics LLC, Mayo Clinic, University of Colorado, Denver
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
09/25
10/25
R-2487-RA01, NCT05961592: R-2487 in Patients with Rheumatoid Arthritis

Recruiting
1
36
US
R-2487, Drug
Rise Therapeutics LLC
Arthritis, Rheumatoid
11/25
01/26

Download Options